Decatur Capital Management Inc. Cuts Stock Holdings in Bristol-Myers Squibb Co (NYSE:BMY)

Decatur Capital Management Inc. decreased its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 2.2% during the second quarter, according to its most recent filing with the SEC. The firm owned 146,728 shares of the biopharmaceutical company’s stock after selling 3,325 shares during the period. Decatur Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $6,654,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Legal & General Group Plc increased its holdings in Bristol-Myers Squibb by 5.9% in the 4th quarter. Legal & General Group Plc now owns 8,568,445 shares of the biopharmaceutical company’s stock worth $445,300,000 after acquiring an additional 474,820 shares in the last quarter. Lodestar Investment Counsel LLC IL lifted its position in shares of Bristol-Myers Squibb by 5.2% during the second quarter. Lodestar Investment Counsel LLC IL now owns 113,720 shares of the biopharmaceutical company’s stock worth $5,157,000 after purchasing an additional 5,579 shares in the last quarter. Perella Weinberg Partners Capital Management LP lifted its position in shares of Bristol-Myers Squibb by 10.9% during the first quarter. Perella Weinberg Partners Capital Management LP now owns 19,431 shares of the biopharmaceutical company’s stock worth $99,000 after purchasing an additional 1,905 shares in the last quarter. Stephens Inc. AR lifted its position in shares of Bristol-Myers Squibb by 30.7% during the first quarter. Stephens Inc. AR now owns 216,532 shares of the biopharmaceutical company’s stock worth $10,331,000 after purchasing an additional 50,798 shares in the last quarter. Finally, Nachman Norwood & Parrott Inc lifted its position in shares of Bristol-Myers Squibb by 3.5% during the second quarter. Nachman Norwood & Parrott Inc now owns 50,388 shares of the biopharmaceutical company’s stock worth $2,285,000 after purchasing an additional 1,687 shares in the last quarter. 77.60% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have recently issued reports on BMY shares. Barclays raised shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $53.00 to $55.00 in a research report on Friday, May 3rd. BMO Capital Markets upped their target price on shares of Bristol-Myers Squibb from $62.00 to $63.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 17th. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $54.00 target price on the stock in a research note on Tuesday, May 7th. UBS Group cut their target price on shares of Bristol-Myers Squibb from $55.00 to $51.00 and set a “neutral” rating on the stock in a research note on Thursday, June 13th. Finally, ValuEngine lowered shares of Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research note on Tuesday, July 2nd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and eight have given a buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus price target of $55.45.

In other Bristol-Myers Squibb news, insider Karen Murphy Santiago sold 3,065 shares of the stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $47.56, for a total value of $145,771.40. Following the transaction, the insider now directly owns 3,066 shares in the company, valued at $145,818.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert J. Bertolini purchased 11,000 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was bought at an average price of $44.72 per share, for a total transaction of $491,920.00. Following the completion of the purchase, the director now directly owns 11,397 shares of the company’s stock, valued at $509,673.84. The disclosure for this purchase can be found here. Corporate insiders own 0.13% of the company’s stock.

Shares of BMY stock traded up $0.79 during trading hours on Friday, reaching $45.99. 17,926,586 shares of the stock were exchanged, compared to its average volume of 14,484,314. The stock has a fifty day moving average price of $45.66. The company has a debt-to-equity ratio of 1.51, a current ratio of 3.88 and a quick ratio of 3.75. Bristol-Myers Squibb Co has a 12-month low of $42.48 and a 12-month high of $63.69. The stock has a market cap of $73.94 billion, a price-to-earnings ratio of 11.56, a P/E/G ratio of 2.24 and a beta of 0.73.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.06 by $0.12. The firm had revenue of $6.27 billion for the quarter, compared to analyst estimates of $6.10 billion. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. The business’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.01 earnings per share. As a group, research analysts predict that Bristol-Myers Squibb Co will post 4.26 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Thursday, August 1st. Shareholders of record on Friday, July 5th were paid a $0.41 dividend. The ex-dividend date was Wednesday, July 3rd. This represents a $1.64 annualized dividend and a yield of 3.57%. Bristol-Myers Squibb’s dividend payout ratio is currently 41.21%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

See Also: Differences Between Momentum Investing and Long Term Investing

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.